Recent Updates — OSTX
OS Therapies completed an initial closing of a warrant exercise inducement offer on October 15, 2026, receiving approximately $7.2 million in gross proceeds. Seven accredited investors exercised or pre-funded existing warrants to purchase 5,517,253 shares at a reduced price of $1.30 per share. In exchange, the company issued new warrants exercisable at $1.40 per share. The offer expires on October 30, 2026, with total expected proceeds reaching approximately $12.3 million if all existing warrants are exercised. Funds will support clinical development and regulatory filings for Herlystic in osteosarcoma. OS Therapies is a clinical-stage oncology company developing gene-edited Listeria-based cancer immunotherapies.
OS Therapies appointed Frank Knuettel II as Chief Financial Officer and Kerry Clem as Chief Commercial Officer effective September 29, 2026. Christopher P. Acevedo stepped down as CFO to serve in a consulting role. Knuettel receives a $300,000 base salary plus equity grants including 750,000 options and 250,000 RSUs. Clem receives a $300,000 base salary with 700,000 options and 200,000 RSUs. The hires support commercial launch preparations for Herlystic in the U.S., U.K., and Europe while managing cash flow via delayed payables and R&D tax credit refunds. OS Therapies is a clinical-stage oncology company developing gene-edited Listeria-based cancer immunotherapies.
OS Therapies Incorporated entered into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026, establishing an at-the-market (ATM) equity offering program. Under this agreement, the company may offer and sell shares of its common stock from time to time up to an aggregate offering price of $75 million. The sales agent receives a commission equal to 3.0% of the gross proceeds, and the company agreed to reimburse legal fees not exceeding $100,000. Net proceeds are intended to fund clinical development activities, advance research programs, and potentially acquire complementary technologies or businesses. OS Therapies operates in the biotechnology industry, focusing on drug discovery and development.
OS Therapies Incorporated entered into a securities purchase agreement for an August Private Placement of senior secured convertible promissory notes with an aggregate subscription amount of up to $10,000,000. The company consummated the initial closing on August 10, 2026, issuing Notes in an aggregate principal amount of $5,405,405.42, along with common stock and warrants. This transaction included the automatic conversion of a previously issued $2,200,000 bridge convertible promissory note into new Notes and equity securities. The Notes bear 9.0% annual interest, mature nine months after funding, and are convertible at $2.05 per share. Warrants to purchase common stock were issued with an exercise price of $2.85 per share for the first tranche. Proceeds will fund clinical development, regulatory activities, working capital, and general corporate purposes. OS Therapies operates in the biotechnology industry, focusing on the discovery and development of novel therapies.